Key result
Angiotensin 1-7 attenuates aldosterone-induced glomerular damage and fibrosis independent of blood pressure in rats.
Why the study?
The relevance of angiotensin 1-7 in hypertensive kidney disease and its underlying molecular-cellular mechanisms were not fully understood.
Does angiotensin 1-7 prevent renal damage in an aldosterone-induced hypertensive rat model?
Does angiotensin 1-7 prevent renal damage in an aldosterone-induced hypertensive rat model?
Angiotensin 1-7 protects against aldosterone-induced hypertensive kidney disease by suppressing TGF-β/FGF-1 pathways and oxidative stress, independent of blood pressure changes.
Answers are grounded in this paper and cite their sources.
Ang1-7 attenuates aldosterone-induced renal fibrosis and oxidative stress in rats independent of BP; leaves open therapeutic relevance in human hypertensive kidney disease.
BACKGROUND: Studies implicate that angiotensin 1-7 (Ang1-7) imparts protective effects in the kidney. However, its relevance in hypertensive kidney disease is not fully understood. The purpose of this study was to explore the role of Ang1-7 on renal damage/remodeling during hypertension and its potential underlying molecular-cellular mechanisms. METHODS: Hypertension was induced in adult Sprague-Dawley rats by infusion of aldosterone (ALDO; 0.75 μg/hour) for 4 weeks with or without co-treatment of Ang1-7 (1 mg/kg/day). Untreated rats served as controls. Systolic blood pressure was monitored by tail-cuff technique. Renal fibrosis was evaluated by picrosirius red staining and renal collagen volume fraction was quantitated using imaging analyzing system. The expression of profibrotic factors [transforming growth factor-β1 (TGF-β1), platelet-derived growth factor-D (PDGF-D), fibroblast growth factor-1 (FGF-1), vascular endothelial growth factor-D (VEGF-D), and tissue inhibitors of metalloproteinases (TIMPs)] and free radical producing enzymes (inducible nitric oxide synthase and nicotinamide adenine dinucleotide phosphate [NADPH] oxidase) in the kidney were examined by reverse transcription-polymerase chain reaction and western blot. Renal oxidative stress was assessed by malondialdehyde (MDA) measurement. RESULTS: Chronic ALDO infusion caused hypertension and hypertensive renal disease represented as glomerular damage/sclerosis. Ang1-7 co-treatment did not affect blood pressure in ALDO-treated rats, but significantly attenuated the glomerular damage/fibrosis. ALDO treatment significantly elevated renal expression of profibrogenic factors, including TGF-β1, TIMP-1/TIMP-2, FGF-1, PDGF-D, and VEGF-D, whereas Ang1-7 co-treatment significantly reduced renal TGF-β1, TIMP-1/TIMP-2, and FGF-1, but not PDGF-D and VEGF-D. Furthermore, ALDO infusion elevated NADPH oxidase (gp91phox) and MDA in the kidney, which was attenuated by Ang1-7 co-treatment. CONCLUSIONS: Ang1-7 plays a protective role in the hypertensive kidney disease independent of blood pressure. The beneficial effects of Ang1-7 are likely mediated via suppressing TGF-β/FGF-1 pathways and oxidative stress.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) studied Hypertensive kidney disease. Angiotensin 1-7 vs. Aldosterone alone and untreated controls was evaluated on Glomerular damage/fibrosis and expression of profibrogenic factors. Angiotensin 1-7 co-treatment significantly attenuated glomerular damage and fibrosis in aldosterone-induced hypertensive rats independent of blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: